PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria:

• Participant must have a diagnosis of moderate or severe COPD.

• Participant must have a post-bronchodilator FEV1/forced vital capacity (FVC) ratio < 0.7.

• Participant must have a post-bronchodilator FEV1 % predicted value ≥ 30% and < 70%.

• Participant must be between 40 and 80 years of age, of either sex, and of any race.

• Participant must be a current or ex-smoker, with a cigarette smoking history of ≥ 10years or > 10 pack-years.

Exclusion Criteria:

• Participant has been diagnosed with asthma or other clinically relevant lung diseaseother than COPD (e.g. restrictive lung diseases, sarcoidosis, tuberculosis,idiopathic pulmonary fibrosis, bronchiectasis, or lung cancer).

• Participant has been diagnosed with α1-antitrypsin deficiency.

• Participant has a body mass greater than 150 kg (330 lb) or less than 40 kg (88 lb).

• Participant has active infection.

• Participant has had a significant exacerbation of COPD or has required mechanicalventilation within 4 weeks of screening.

• The participant with clinically relevant uncontrolled medical condition notassociated with COPD.

• Participant has documented history of uncontrolled heart failure.

• Participant has pulmonary hypertension due to left heart condition.

• Participant has atrial fibrillation or significant congenital heart defect/disease.

• Participant has initiated pulmonary rehabilitation within 3 months of screening.

• Participant is allergic to bovine or porcine products.

• Participant has evidence of active malignancy, or prior history of active malignancythat has not been in remission for at least 5 years.

• Participant has a life expectancy of < 6 months.